Skip to main content
Clinical Trials/CTRI/2022/07/044231
CTRI/2022/07/044231
Completed
Phase 3

Comparative evaluation of efficiency oftransdermal patches of ketoprofen and diclofenacsodium with oral diclofenac tablet on postendodontic pain reduction following single visitroot canal therapy in symptomatic irreversiblepulpitis- A Randomized Clinical Study. ?

DR PRIYA PORWA0 sites78 target enrollmentTBD

Overview

Phase
Phase 3
Intervention
Not specified
Conditions
Not specified
Sponsor
DR PRIYA PORWA
Enrollment
78
Status
Completed
Last Updated
2 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
TBD
End Date
October 26, 2022
Last Updated
2 years ago
Study Type
Interventional

Investigators

Sponsor
DR PRIYA PORWA

Eligibility Criteria

Inclusion Criteria

  • Patients complaining of pain in anterior or single\-rooted premolar teeth of either jaw
  • and diagnosed as symptomatic irreversible pulpitis with or without apical periodontitis
  • having pre operative moderate to severe pain indicated for single visit endodontics will
  • be included in the study.
  • A written informed consent will be taken from all the patients and only those patients
  • ready to sign the consent letter will be included in the study

Exclusion Criteria

  • 1\. Patients with known hypersensitivity against ketoprofen or diclofenac sodium will be excluded from the study.
  • 2\. patients with history of allergic reactions such as bronchospasm, shock, urticarial,
  • etc., following the use of non\-steroidal anti\-inflammatory drugs (NSAIDs) will be excluded from the study.
  • 3\. Patients with high blood pressure and cardiac conditions will be excluded from the study.
  • 4\. Patients with sinus drainage, pus discharge, acute or chronic apical abscess will be excluded from the study.
  • 5\. Intentional RCT, fractured tooth having cracks or resorption will be excluded from
  • 6\. Patients with active stomach or duodenal ulceration within the last 6 months will be excluded from the study.
  • 7\. Patients undergoing treatment with other NSAIDs or corticosteroids during the
  • study period will be excluded from the study.
  • 8\. Patients with developmental anomalies, congenital defects, pathology or open apex,

Outcomes

Primary Outcomes

Not specified

Similar Trials